NCT05647343View on ClinicalTrials.gov

Study to Assess the Safety and Pharmacokinetics of ATL-001 (Ciclopirox Olamine) in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

March 31, 2023

Primary Completion Date

April 8, 2024

Study Completion Date

April 8, 2024

Conditions
Adverse Effect of Drugs and Medicaments in Therapeutic Use
Interventions
DRUG

Ciclopirox Olamine Oral

On the morning of Day 1 to Day 5, each participant will receive a single oral dose of ATL-001 or placebo

OTHER

Placebo

On the morning of Day 1 to Day 5, each participant will receive a single oral dose of ATL-001 or placebo

Trial Locations (1)

08009

Hassman Research Institute, LLC, Berlin

Sponsors
All Listed Sponsors
lead

Atlas Molecular Pharma

INDUSTRY

NCT05647343 - Study to Assess the Safety and Pharmacokinetics of ATL-001 (Ciclopirox Olamine) in Healthy Volunteers | Biotech Hunter | Biotech Hunter